Medidata Entry Selected for Patient Engagement App Challenge Prize at 23rd Annual Partnerships in Clinical Trials Conference
Medidata (NASDAQ: MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, won the Patient Engagement App Challenge (large organization category) at the 23rd Annual Partnerships in Clinical Trials Conference with a unique mobile app. The award recognizes Engage, Medidata’s app prototype, for its potential to positively transform the clinical trial experience for study participants at a time when capturing the voice of the patient is becoming increasingly important.
An easy-to-use, device-agnostic app that patients can access via their personal smartphones or other mobile devices, Engage is designed to educate, engage and empower study participants. It complements Medidata Patient Cloud™, a solution for patient-centric data capture and management offered as part of the industry-leading Medidata Clinical Cloud™, a comprehensive, seamless technology platform for the planning, setup and execution of clinical trials.
“Medidata’s vision for transforming clinical trials is based on engaging patients in new and innovative ways,” said Glen de Vries, Medidata’s president. “By leveraging the smartphones, tablets and other mobile devices that study participants already have, we can provide continuous feedback as well as targeted messages to improve patient education, adherence, communications with their healthcare providers and outcomes.”
A team of Medidata engineers developed Engage during company-sponsored innovation time, a program Medidata put in place that allows employees to think creatively about solving problems and use technology in different ways. Engage creates new connections between patients, physicians and sponsors, but is built on top of Medidata’s industry-leading, cloud-based platform.
“While at this stage Engage is only a prototype, it is an example of how Medidata is innovating and developing new ideas for our platform and solution roadmaps,” said Michelle Marlborough, Medidata’s vice president of product strategy. “We have so many talented engineers at Medidata, and we are committed to supporting them with the time and freedom to be creative. They have great ideas with tremendous potential to transform drug development and make a real difference in the lives of patients.”
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.